Lower Prices for Gilead HIV Medicines under ADAPs, Effective July 1, 2010
New Pricing Frozen to ADAPs through 2013
Key Enhancements Made to Gilead HIV Patient Assistance and Co-Pay Programs
FOSTER CITY, Calif. & WASHINGTON–(Business Wire)–
Gilead Sciences and the ADAP Crisis Task Force (ACTF) today announced a series
of initiatives to help state AIDS Drug Assistance Programs (ADAPs) continue to
provide antiretroviral medicines to people living with HIV in the United States.
The new measures are a response to budget shortfalls being experienced by a
number of ADAPs across the country, and the growing number of individuals on
ADAP waiting lists who are not receiving the HIV treatment they need.
The initiatives announced today by Gilead and the ACTF include:
* Additional discounts and extension of pricing freeze to ADAPs for Truvada®
(emtricitabine and tenofovir disoproxil fumarate), Viread® (tenofovir disoproxil
fumarate) and Emtriva® (emtricitabine) through December 31, 2013
* Expanded eligibility for Gilead`s patient assistance program
* Elimination of minimum payment for patients through Gilead`s co-pay assistance
* Support for creation of “universal” patient assistance application
As of May 20, 2010, there were 1,143 individuals on ADAP waiting lists in 10
states. ADAP waiting lists have increased more than ten-fold in the last year
(99 individuals were on ADAP waiting lists in May 2009). In addition to waiting
lists, 16 states have implemented other access restrictions such as lowering
financial eligibility criteria, removing drugs from their formularies and
“Gilead`s willingness to help with the current ADAP crisis by agreeing to these
initiatives demonstrates that they are committed to serving the needs of people
living with HIV in the U.S. who have no access to life-saving medicines except
through ADAP,” stated Jennifer Brown, Director of the Bureau of Epidemiology at
the Utah Department of Health and spokesperson for the ACTF. “The ADAP Crisis
Task Force and Gilead Sciences have come together to find ways to bridge the gap
that ADAPs are experiencing, strengthening the case for further assistance from
the federal and state governments at this critical time of unprecedented need
for ADAPs and their clients,” added Brown.
“Gilead is committed to ensuring that a drug`s price is never a barrier to
access for those in need,” said Kevin Young, Executive Vice President,
Commercial Operations, Gilead Sciences. “As one of the first companies to freeze
pricing for ADAPs in 2008, we remain focused on developing solutions that ensure
that individuals living with HIV, regardless of where they live or their income
level, have access to our therapies.”
New Lower Prices and Extension of ADAP Price Freeze
Effective July 1, 2010, Gilead will set lower ceiling prices for its HIV
medicines Truvada, Viread and Emtriva. The revised prices will include
supplemental discounts that are in addition to any federally-mandated discounts.
Additionally, Gilead`s new ceiling prices will be frozen through December 31,
2013. This extends Gilead`s original ADAP price freeze that was established in
2008 and continued through 2010. Taken together, these changes will result in
lower net prices for ADAPs.
Expanded Eligibility for Gilead Patient Assistance Program
Gilead`s U.S. Advancing Access® patient assistance program was developed in
conjunction with feedback from advocates in the HIV community. The program
utilizes a rapid and simple process that ensures clients who apply and qualify
for assistance can receive immediate, same-day access to Gilead`s
Effective on or before July 1, 2010, Gilead will increase the income eligibility
guidelines of this program from 300 percent of the Federal Poverty Guidelines to
500 percent of the Federal Poverty Guidelines as published by the U.S.
Department of Health and Human Services.
This change results in income criteria that currently matches or exceeds all
state ADAPs. This is an important change for clients eligible for ADAPs but on
waiting lists as all now will have access to this program until they are
accepted into ADAP. Clients seeking further information on the program should
contact U.S. Advancing Access at 1-800-226-2056, Monday through Friday between
9:00 a.m. and 8:00 p.m. (Eastern).
Enhanced Co-Pay Assistance Program
Effective on or before July 1, 2010, Gilead will eliminate the requirement for
clients with private insurance to pay the first $50 of out-of-pocket expenses
before co-pay assistance begins. Going forward, Gilead will pay up to $200 per
month ($2,400/year) toward out-of-pocket expenses for Truvada, Viread or
Emtriva. All clients in the U.S. with private insurance are eligible, except
where prohibited by law. Clients seeking further information on Gilead`s co-pay
program should call 1-888-358-0398 to request a pharmacy Co-Pay Card for use
when filling prescriptions.
New Effort to Create Universal Patient Assistance Program Application
Gilead recognizes the challenges that case managers and client advocates face in
coordinating access to care across multiple pharmaceutical company patient
assistance programs. Gilead therefore supports and will participate in a new
collaboration between industry and community partners to develop a universal
application system for patient assistance programs that would simplify access to
HIV combination therapy for clients requiring medications from different
About the ADAP Crisis Task Force (ACTF) and the National Alliance of State and
Territorial AIDS Directors (NASTAD)
The ADAP Crisis Task Force (ACTF) was formed in December 2002 by a group of
state AIDS/ADAP directors concerned about the nationwide fiscal crisis facing
ADAPs. The ACTF works with pharmaceutical manufacturers of antiretroviral
medications to reduce drug costs and improve access to medications for clients
in the nation`s ADAPs. NASTAD provides logistical support for the ACTF. Founded
in 1992, NASTAD is a nonprofit national association of state and territorial
health department HIV/AIDS program directors who have programmatic
responsibility for administering HIV/AIDS and viral hepatitis health care,
prevention, education, and supportive services programs funded by state and
federal governments. For more information, visit www.NASTAD.org.
About Gilead Sciences
Gilead Sciences (Nasdaq: GILD) is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of unmet medical
need. The company`s mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Australia.
This press release includes forward-looking statements, within the meaning of
the Private Securities Litigation Reform Act of 1995, that are subject to risks,
uncertainties and other factors, including the risk that Gilead may modify
aspects of its ADAP-related drug pricing prior to December 31, 2013 or change
the arrangements under its patient assistance or co-pay assistance programs in
the future. These risks, uncertainties and other factors could cause actual
results to differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these forward-looking
statements. These and other risks are described in detail in Gilead`s Quarterly
Report on Form 10-Q for the first quarter of 2010, as filed with the U.S.
Securities and Exchange Commission. Gilead claims the protection of the Safe
Harbor contained in the Private Securities Litigation Reform Act of 1995 for
forward-looking statements. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
Full U.S. prescribing information for Truvada is available at www.truvada.com.
Full U.S. prescribing information for Viread is available at www.viread.com.
Full U.S. prescribing information for Emtriva is available at www.gileadhiv.com.
Truvada, Viread and Emtriva are registered trademarks of Gilead Sciences, Inc.
Murray Penner, 202-434-8090
Amy Flood, 650-522-5643
Copyright Business Wire 2010